Investigators commissioned by the US Centers for Medicare & Medicaid Services (CMS) said compendia of medications used to justify off-label use for cancer treatments appear not to use systematic methods to review or update evidence. As a result, physicians using these compendia to determine treatment regimens for patients with cancer may not be prescribing the best medications for a particular case, and Medicare and other insurers may be paying for suboptimal care for such patients.
Mitka M. Off-Label Cancer Drug Compendia Found Outdated and Incomplete. JAMA. 2009;301(16):1645-1646. doi:10.1001/jama.2009.536